Table 3 Neuropsychiatric, motor and quality of life scores at baseline and at 6 months.
From: A randomized controlled double-blind study of rotigotine on neuropsychiatric symptoms in de novo PD
Placebo | Rotigotine | F | P | |||
|---|---|---|---|---|---|---|
Baseline | 6 months | Baseline | 6 months | |||
Apathy (LARS) | −11 ± 6.9 (−21; 2) | −17.6 ± 9.5 (−34; 1) | −13.7 ± 6.9 (−21; 4) | −21.7 ± 8.8 (−33; −2) | 0.24 | 0.6268 |
Depression (BDI-2) | 18.1 ± 6.1 (5; 29) | 14.5 ± 7.4 (3; 26) | 17 ± 8.7 (4; 35) | 12.2 ± 8.9 (2; 35) | 0.29 | 0.5945 |
Anxiety (STAI-state) | 41.5 ± 11.3 (21; 61) | 39.1 ± 10.4 (20; 55) | 38.7 ± 11.2 (23; 70) | 36 ± 12 (20; 67) | 0.01 | 0.9360 |
Anxiety (STAI-trait) | 51.8 ± 9.4 (33; 66) | 50.5 ± 9.5 (30; 71) | 50.2 ± 8.7 (32; 64) | 43.5 ± 10.9 (26; 64) | 4.45 | 0.0405 |
Apathy (Starkstein apathy scale) | 20.5 ± 4.8 (11; 29) | 18.8 ± 6.4 (6; 29) | 18.6 ± 3.7 (13; 28) | 14 ± 5.8 (5; 23) | 2.57 | 0.1156 |
Apathy (Ardouin) | 2.41 ± 0.67 (1; 4) | 1.76 ± 1.09 (0; 4) | 2.15 ± 0.67 (1; 4) | 1 ± 0.94 (0; 3) | 2.82 | 0.1002 |
Depression (Ardouin) | 1.36 ± 0.95 (0; 3) | 1.27 ± 1.08 (0; 3) | 1.31 ± 0.93 (0; 3) | 0.77 ± 0.86 (0; 3) | 1.82 | 0.1837 |
Anxiety (Ardouin) | 1.68 ± 1.13 (0; 4) | 1.36 ± 1 (0; 3) | 1.38 ± 0.94 (0; 3) | 0.85 ± 0.92 (0; 3) | 0.71 | 0.4024 |
Hyperdopaminergic behaviors (Ardouin) | 0.95 ± 1.29 (0; 4) | 1.27 ± 1.32 (0; 4) | 0.72 ± 1.28 (0; 5) | 2.44 ± 2.27 (0; 7) | 6.82 | 0.0122 |
MDS-UPDRS III | 25.1 ± 9.4 (8; 48) | 28.4 ± 12 (11; 54) | 27.8 ± 10.8 (12; 57.5) | 25.9 ± 11.6 (4; 47) | 6.33 | 0.0154 |
PDQ-39 | 5.7 ± 2.4 (2; 12.3) | 5.3 ± 2.1 (2.1; 10) | 5.9 ± 2.6 (2.3; 11.6) | 6.0 ± 2.5 (2; 11.6) | 1.18 | 0.2825 |
